AI in Pharma

| December 1, 2019

article image
Artificial intelligence (AI) can accelerate decision-making and leverage insights in drug development that have not been used before. Günther Illert, founder of Healthcare Shapers, interviews Janik Jaskolski, CEO of Semalytix, about their innovative approach.

Spotlight

i3 Research

i3 is a global pharmaceutical services company that provides integrated strategies and solutions throughout the product lifecycle.i3 Advantage: Your i3 projects and staffing solutions will benefit from the many resources uniquely available to i3 through our corporate ties. i3 is a business unit of Ingenix, a wholly-owned subsidiary of UnitedHealth Group. Ingenix provides knowledge and information services Intelligence for Health Care to UnitedHealth Group businesses.

OTHER ARTICLES

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | March 6, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Spotlight

i3 Research

i3 is a global pharmaceutical services company that provides integrated strategies and solutions throughout the product lifecycle.i3 Advantage: Your i3 projects and staffing solutions will benefit from the many resources uniquely available to i3 through our corporate ties. i3 is a business unit of Ingenix, a wholly-owned subsidiary of UnitedHealth Group. Ingenix provides knowledge and information services Intelligence for Health Care to UnitedHealth Group businesses.

Events